compounded semaglutide noom Unboxing GLP-1ᴿˣ Noom GLP-1rx Plus Program —

doi: 10.1079/BJN20041061

Yes, many patients remain on GLP-1 therapy long-term because obesity meets the clinical definition of a chronic disease requiring ongoing management

GLP-1 treatment protects against EndMT through inhibiting the activation of poly (ADP-ribose) polymerase 1 (PARP-1) which can elicit Smad3 and transforming growth factor (TGF)-1 responses

The Confidence Factor: Weight Loss as a Path Back to Yourself Weight loss is rarely just about the number on the scale

Participants receiving tirzepatide at maximum doses achieved average weight losses of 2022% of baseline body weight, while semaglutide trials reported 1417% reductions